A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

References

• Dvorak H F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368–4380
   PubMed Web of Science ®Google Scholar
• Benjamin L E, Keshet E. Conditioning switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94: 8761–8766
   PubMed Web of Science ®Google Scholar
• Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci P F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504–509
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 167–172
   Google Scholar
• Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 68: 91–100
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, Joensuu H, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors, VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Marinelli R J, Kapp A V, Tibshirani R J, Hammer A S, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007; 170: 1362–1369
   PubMed Web of Science ®Google Scholar
• Bellamy W T, Richter L, Frutiger Y, Grogan T M. Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728–733
   PubMed Web of Science ®Google Scholar
• Kim K J, Li B, Winer J, Houck K, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 71: 53–64
   Google Scholar
• Yang J C, Haworth L, Sherry R M, Hwu P, Schwartzentruber D J, Topalian S L, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–434
   PubMed Web of Science ®Google Scholar
• Cobleigh M A, Langmuir Vk, Sledge G W, Miller K D, Haney L, Novotny W F, et al. Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 5(Suppl. 16)117–124
   Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Byrne G J, Ghellal A, Iddon J, Blann A D, Venizelos V, Kumar S, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000; 92: 1329–1336
   PubMed Web of Science ®Google Scholar
• Stopeck A T, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A, et al. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002; 8: 2798–2805
   PubMed Web of Science ®Google Scholar
• Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 2643–2650
   PubMed Web of Science ®Google Scholar
• Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001; 61: 4341–4344
   PubMed Web of Science ®Google Scholar
• Motzer R J, Michaelson M D, Redman B G, Hudes G R, Wilding G, Figlin R A, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoman. J Clin Oncol 2006; 24: 16–24
   PubMed Web of Science ®Google Scholar
• DePrimo S E, Bello C L, Smeraglia J, Baum C M, Spinella D, Rini B I, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma:modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32
   PubMed Web of Science ®Google Scholar
• Gordon M S, Margolin K, Talpaz M, Sledge G W, Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–850
   PubMed Web of Science ®Google Scholar
• Glade Bender J L, Adamson P C, Reid J M, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children's oncology group study. J Clin Oncol 2008; 26: 399–405
   PubMed Web of Science ®Google Scholar
• Mancuso P, Colleoni M Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452–459
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Tibshirani R J, Hsi E D, Hans C P, Pohlman B, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38–47
   PubMed Web of Science ®Google Scholar
• Ganjoo K N, An C S, Robertson M J, Gordon L I, Sen J A, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker, and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005
   PubMed Web of Science ®Google Scholar
• Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I, et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 2089–2093
   PubMed Web of Science ®Google Scholar
• Breen E C. VEGF in biological control. J Cell Biochem 2007; 102: 1358–1367
   PubMed Web of Science ®Google Scholar
• Wang E S, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin D J, Moore M A, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893–2902
   PubMed Web of Science ®Google Scholar
• Buckstein R, Kerbel R S, Shaked Y, Nayar R, Foden C, Turner R, et al. High-dose celeboxib and metronomic ‘low-dose’ cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 5190–5198
   PubMed Web of Science ®Google Scholar
• Bertolini F. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. Cancer Metastasis Rev 2008; 27: 95–101
   PubMed Web of Science ®Google Scholar
• Khan S S, Solomon M A, McCoy J P, Jr., et al. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005; 64: 1–8
   PubMed Web of Science ®Google Scholar
• Gerber H P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671–680
   PubMed Web of Science ®Google Scholar
• Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
   PubMed Web of Science ®Google Scholar
• De Vos S, Hofmann W K, Grogan T M, Krug U, Schrage M, Miller T P, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003; 83: 271–285
   PubMed Web of Science ®Google Scholar